Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival
- PMID: 24998423
- DOI: 10.1016/j.ijid.2014.05.012
Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival
Abstract
Background: Blood stream infections (BSIs) due to carbapenem-resistant Enterobacteriaceae (CRE) are associated with high hospital mortality rates and present a tremendous challenge to clinicians. The optimal treatment remains undefined. We aimed to investigate the risk factors for mortality and the correlation between different treatment modalities and outcomes.
Methods: The clinical characteristics and treatment outcomes of a cohort of 36 patients with BSIs due to CRE were investigated and a retrospective nested case-control study of surviving and non-surviving patients was conducted.
Results: Fifty percent of the cases were male and the mean patient age was 54.9 ± 15.8 years. Klebsiella pneumoniae was the etiological agent in 26 cases (72.2%), Escherichia coli in eight (22.2%), and Enterobacter aerogenes in two (5.5%). All strains were phenotypically positive for carbapenemase activity and all except two (one E. coli and one K. pneumoniae) yielded both blaOXA-48 carbapenemases and blaCTX-M-type extended-spectrum beta-lactamases (ESBLs) in PCR products. The 14-day, 28-day, and all-cause in-hospital mortality rates were 41.6%, 50%, and 58.3%, respectively. The median time to death was 8 days (range 2-52 days). No significant differences were observed between survivors and non-survivors in terms of baseline characteristics, comorbid conditions, etiologies, or sources of bacteremia, however hematological malignancies (p=0.015) and prolonged neutropenia (p=0.044) were more common in non-survivors. Microbiological eradication and clinical response within 7 days were two major determinants of 28-day attributable mortality (p=0.001 and p=0.001, adjusted r(2)=0.845). Colistin-based dual combinations, and preferably triple combinations, were associated with significantly better outcomes when compared to non-colistin-based regimens (p<0.001). Time to active treatment had a significant effect on the course of infection (p=0.014).
Conclusion: Earlier active treatment with colistin based regimens and microbiological and clinical response within 7 days are major predictors of survival in cases of BSIs due to CRE. Rectal screening offers the advantage of earlier recognition and prompt empirical treatment.
Keywords: Blood stream infection; Carbapenemase; Enterobacteriaceae; OXA-48; Survival; Treatment.
Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia.Clin Infect Dis. 2017 Feb 1;64(3):257-264. doi: 10.1093/cid/ciw741. Epub 2016 Nov 9. Clin Infect Dis. 2017. PMID: 28013264 Free PMC article.
-
National survey of colistin resistance among carbapenemase-producing Enterobacteriaceae and outbreak caused by colistin-resistant OXA-48-producing Klebsiella pneumoniae, France, 2014.Euro Surveill. 2016 Sep 15;21(37):30339. doi: 10.2807/1560-7917.ES.2016.21.37.30339. Euro Surveill. 2016. PMID: 27685838 Free PMC article.
-
Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella.J Microbiol Immunol Infect. 2006 Dec;39(6):496-502. J Microbiol Immunol Infect. 2006. PMID: 17164953
-
[Infectious diseases caused by carbapenemase-producing Enterobacteriaceae--a particular challenge for antibacterial therapy].Med Monatsschr Pharm. 2014 May;37(5):162-72; quiz 173-4. Med Monatsschr Pharm. 2014. PMID: 24908928 Review. German.
-
Carbapenemase-producing Enterobacteriaceae.Semin Respir Crit Care Med. 2015 Feb;36(1):74-84. doi: 10.1055/s-0035-1544208. Epub 2015 Feb 2. Semin Respir Crit Care Med. 2015. PMID: 25643272 Free PMC article. Review.
Cited by
-
Phenotypic and genotypic characteristics of carbapenem-resistant Enterobacteriaceae in a tertiary-level reference hospital in Turkey.Ann Clin Microbiol Antimicrob. 2016 Apr 6;15:20. doi: 10.1186/s12941-016-0136-2. Ann Clin Microbiol Antimicrob. 2016. PMID: 27048322 Free PMC article.
-
Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections.Open Forum Infect Dis. 2015 May 5;2(2):ofv050. doi: 10.1093/ofid/ofv050. eCollection 2015 Apr. Open Forum Infect Dis. 2015. PMID: 26125030 Free PMC article. Review.
-
Profile of Enterobacteria Resistant to Beta-Lactams.Antibiotics (Basel). 2020 Jul 15;9(7):410. doi: 10.3390/antibiotics9070410. Antibiotics (Basel). 2020. PMID: 32679663 Free PMC article.
-
OXA-48-Like β-Lactamases: Global Epidemiology, Treatment Options, and Development Pipeline.Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0021622. doi: 10.1128/aac.00216-22. Epub 2022 Jul 20. Antimicrob Agents Chemother. 2022. PMID: 35856662 Free PMC article. Review.
-
Laboratory Detection and Clinical Implication of Oxacillinase-48 like Carbapenemase: The Hidden Threat.J Glob Infect Dis. 2016 Jan-Mar;8(1):41-50. doi: 10.4103/0974-777X.176149. J Glob Infect Dis. 2016. PMID: 27013843 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical